China Medical System enters collaboration agreement with Mabgeek Biotechnology
China Medical System (CHSYF) entered into a Collaboration Agreement with Hunan Mabgeek Biotechnology and its subsidiary for Class 1 innovative drug anti-IL-4Ralpha humanized monoclonal antibody injection MG-K10. The Group has obtained the co-development right as specifically agreed upon in the Agreement and exclusive commercialization right to the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and Singapore; Mabgeek Biotechnology will support the commercialization activities and is responsible for the sale and supply of the Product. The collaboration term is perpetual. IL-4Ralpha is considered a key target for the treatment of type 2 inflammatory diseases, such as atopic dermatitis, asthma, prurigo nodularis, etc. Anti-IL-4Ralpha monoclonal antibodies are among the best-selling biologics in this field. MG-K10 is an innovative long-acting anti-IL-4Ralpha humanized monoclonal antibody that simultaneously blocks the signaling of key type 2 inflammatory cytokines IL-4 and IL-13. Following Fc mutation, MG-K10 allows long dosing interval owing to its prolonged half-life, and it is expected to be the first long-acting anti-IL-4Ralpha monoclonal antibody marketed in China. Currently marketed anti-IL-4Ralpha drugs require dosing every two weeks, whereas MG-K10 only requires dosing every four weeks, demonstrating good efficacy and safety. MG-K10 has the potential to be the Best-in-Class/
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CHSYF:
#China #Medical #System #enters #collaboration #agreement #Mabgeek #Biotechnology